Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by BMO Capital Markets

BMO Capital Markets reiterated their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report released on Tuesday morning, Benzinga reports. They currently have a $1,300.00 price objective on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on REGN. TD Cowen upped their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a buy rating in a report on Tuesday, July 23rd. Argus raised their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a buy rating in a research report on Tuesday, June 25th. Piper Sandler lifted their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an overweight rating in a research note on Friday, August 23rd. Canaccord Genuity Group reissued a buy rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Finally, Leerink Partners restated a market perform rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of Moderate Buy and an average target price of $1,118.62.

Regeneron Pharmaceuticals Stock Up 0.9 %

Regeneron Pharmaceuticals stock opened at $1,039.96 on Tuesday. Regeneron Pharmaceuticals has a 52 week low of $769.19 and a 52 week high of $1,211.20. The stock has a market cap of $114.59 billion, a price-to-earnings ratio of 30.72, a PEG ratio of 3.72 and a beta of 0.12. The company’s 50-day moving average price is $1,129.87 and its two-hundred day moving average price is $1,033.99. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the business earned $8.79 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now owns 17,882 shares in the company, valued at $18,941,329.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,270 shares of company stock worth $10,695,833. Corporate insiders own 7.48% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Sachetta LLC lifted its holdings in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $26,000. West Paces Advisors Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the period. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $28,000. Finally, Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $33,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.